SPR720

06
Feb

SPR720

February 6, 2019
The purpose of this clinical trial is to evaluate SPR720 in a double-blind, placebo-controlled study in healthy subjects consisting of single ascending dose and multiple ascending dose cohorts. SPR720 is an orally administered antimicrobial agent being developed for the treatment of nontuberculous mycobacterial (NTM) infections. The advancement of SPR720 into the Phase 1 clinical assessment was...
Read More
28
Aug

Arikayce

August 28, 2018
Arikayce for Nontuberculous Mycobacteria The purpose of this randomized, placebo-controlled study is to evaluate the efficacy, safety and tolerability of 84 days of daily dosing of 590 mg of liposomal amikacin for inhalation (LAI) versus placebo in patients with recalcitrant Mycobacterium avium complex lung disease. The primary outcome measure is proportion of subjects with culture...
Read More

WHAT IS NTM?

“NTM” is short for Nontuberculous Mycobacteria. NTM disease is a serious chronic lung illness.

Learn More